Full-Time

Contract – AI Engineer

Confirmed live in the last 24 hours

Cytokinetics

Cytokinetics

501-1,000 employees

Develops drugs for muscle function disorders

Biotechnology
Healthcare

Compensation Overview

$85 - $120Hourly

Junior, Mid

San Bruno, CA, USA

Category
Applied Machine Learning
Natural Language Processing (NLP)
AI & Machine Learning
Required Skills
Microsoft Azure
Python
NoSQL
Tensorflow
Git
Data Structures & Algorithms
Pytorch
SQL
Docker
AWS
Google Cloud Platform
Requirements
  • Bachelor's degree in Computer Science, Engineering, or related field
  • 1-3 years’ experience with large language models like Claude, GPT-4 ideally in an industry setting
  • Proficiency in Python and modern development environments including Git, Anaconda, PiP, Docker, and Cloud services
  • Ability to develop production-ready standalone libraries beyond notebook code.
  • Individual contributor mindset, with strong problem-solving and communication skills
  • Demonstrable previous work with LLM interfaces, sharing code repositories if applicable during the interview process.
  • Proven experience in development using Python, AI and machine learning tools such as PyTorch and TensorFlow. Knowledge in clinical development is a plus.
  • Strong understanding of database management, including SQL and NoSQL databases.
  • Able to train and fine-tune AI models (LLMs) and integrate with current state of the art solutions.
  • Experience with cloud platforms such as Microsoft Azure or AWS.
  • Hands-on experience with cloud data engineering tools.
  • Knowledge of Cloud Composer for orchestrating data workflows.
  • Knowledge of GCP requirements and pharmaceutical related regulations
  • Excellent problem-solving skills and attention to detail.
  • Ability to work effectively in a fast-paced and dynamic environment.
Responsibilities
  • Collaborate with Teams: Engage in meetings with diverse stakeholders to understand workflows and provide insights. Educate teams on the potential and boundaries of integrating LLMs into existing systems.
  • Craft LLM Prompts: Creatively design the prompts necessary to guide LLMs towards specific tasks, ensuring alignment with desired outcomes.
  • Develop Integration Software: Construct robust software to process LLM responses and enable integration with existing applications.
  • Implement Intelligent Constraints: Design constraints to prevent users from asking questions that LLMs cannot answer, maintaining alignment with the task objectives.
  • Assess and Mitigate Security Risks: Monitor and evaluate potential security risks like prompt injection or sensitive data leakage, implementing necessary security protocols.
  • Coordinate Complex AI Tasks: Design agents to manage intricate tasks such as multi-database SQL queries or automated workflows.
  • Experiment and Innovate: Lead experiments to test LLM communications, analyzing responses to ensure desired results, and iteratively refine processes.
  • Participate in Design Meetings, Standups, and Planning Sessions: Engage in the necessary meetings to develop and deliver solutions within the team.
  • Develop and maintain backend services using Python, focusing on AI-driven applications on cloud platforms.
  • Optimize database performance and manage complex data structures for AI models.
  • Design and implement APIs for seamless integration with AI models and applications.
  • Collaborate with data/AI professionals to integrate machine learning models into production systems.
  • Ensure the security and compliance of clinical trial data, adhering to GCP requirements and other regulations.
  • Collaborating with clinical systems specialists, data scientists, and other stakeholders to understand data requirements and build appropriate solutions for clinical development.
  • Participate in code reviews, testing, and quality assurance processes.
  • Diagnose and resolve issues related to AI model deployment and backend infrastructure.
  • Document development processes, system designs, and architectural decisions.

Cytokinetics focuses on developing medicines that improve muscle function for patients with cardiovascular and neuromuscular diseases. Their products are small molecule drugs designed to either enhance or inhibit muscle function, depending on the condition being treated. For example, they are working on drugs for heart failure, hypertrophic cardiomyopathy, amyotrophic lateral sclerosis, and spinal muscular atrophy. What sets Cytokinetics apart from competitors is their specific focus on muscle-related conditions and their extensive pipeline of drugs currently in clinical trials. The company's goal is to bring effective treatments to market that address the unmet needs of patients suffering from these debilitating diseases.

Company Stage

IPO

Total Funding

$58.4M

Headquarters

South San Francisco, California

Founded

1998

Growth & Insights
Headcount

6 month growth

2%

1 year growth

1%

2 year growth

15%
Simplify Jobs

Simplify's Take

What believers are saying

  • Successful Phase III trial results for aficamten in treating obstructive hypertrophic cardiomyopathy (HCM) highlight the company's potential for market leadership in this area.
  • The $575M funding from Royalty Pharma ensures strong financial support for the commercial launch of aficamten and further R&D activities.
  • Recent investments and stock offerings indicate strong investor confidence and provide additional capital for growth and development.

What critics are saying

  • The late-stage biopharmaceutical market is highly competitive, with significant pressure to bring drugs to market quickly and efficiently.
  • Dependence on the success of clinical trials and regulatory approvals poses inherent risks, as any setbacks could delay commercialization and revenue generation.

What makes Cytokinetics unique

  • Cytokinetics focuses on muscle function improvement for cardiovascular and neuromuscular diseases, a niche area with high unmet medical needs.
  • The company has a robust pipeline of small molecule muscle activators and inhibitors, setting it apart from competitors with more generalized drug portfolios.
  • Strategic funding collaborations, such as the $575M deal with Royalty Pharma, provide significant financial backing for their R&D and commercialization efforts.

Help us improve and share your feedback! Did you find this helpful?